In a research report published Tuesday, Cantor analyst Chiara Russo reiterated an Overweight rating on shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN), with a price target of $6.00, after the company pre-announced its 2016 earnings beat and 2017 guidance last week.
Russo noted, “We met with management briefly at a conference in San Francisco, where it was pointed out that the strength seen in 2Q revenue simply continued through the year, allowing for a “modest” YE beat. Vascepa historically sees a 1Q seasonal dip, even so with current guidance, YoY revenue growth could be ~20-25% based on the 2017 guidance midpoint of $160M. In addition, management noted that the multitude of secondary endpoints in the REDUCE-IT outcomes trial should not be overlooked. Potential benefit seen in large subpopulations such as diabetics, coupled with a very well-tolerated safety profile, could meaningfully expand the value proposition beyond treatment for high triglycerides, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chiara Russo has a yearly average return of 1.2% and a 49% success rate. Russo has a 2.0% average return when recommending AMRN, and is ranked #1982 out of 4347 analysts.
Out of the 5 analysts polled by TipRanks, 4 rate Amarin stock a Buy, while 1 rates the stock a Hold. With a return potential of 110%, the stock’s consensus target price stands at $6.38.